A stimulating new target for cancer immunotherapy
Lancet
.
1999 Oct 9;354(9186):1225-7.
doi: 10.1016/S0140-6736(99)90130-7.
Authors
J Schultze
1
,
P Johnson
Affiliation
1
Department of Adult Oncology, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, USA.
PMID:
10520628
DOI:
10.1016/S0140-6736(99)90130-7
No abstract available
Publication types
Review
MeSH terms
Animals
CD40 Antigens / therapeutic use*
Humans
Immunotherapy
Mice
Neoplasms, Experimental / therapy*
T-Lymphocytes / immunology
Substances
CD40 Antigens